Related Experiment Video

Updated: Jul 18, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Sphingosine kinase-1--a potential therapeutic target in cancer

Olivier Cuvillier1

  • 1Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, 205 route de Narbonne, 31077 Toulouse, France. olivier.cuvillier@ipbs.fr

Anti-Cancer Drugs
|December 13, 2006
PubMed

Insights

Sphingosine kinase-1 regulates cell survival and apoptosis by controlling sphingolipid levels. Inhibiting this enzyme may offer a therapeutic strategy against cancer by promoting tumor cell death.

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Molecular Oncology

Background:

  • Sphingolipids, including ceramide, sphingosine, and sphingosine 1-phosphate, are critical regulators of cell survival and apoptosis.
  • Sphingosine 1-phosphate promotes cell proliferation and survival, while ceramide and sphingosine induce apoptosis or cell growth arrest.
  • The balance of these sphingolipids is tightly controlled by enzymes, with sphingosine kinase-1 playing a key role.

Purpose of the Study:

  • To investigate the role of sphingosine kinase-1 in regulating sphingolipid metabolism and its implications in cancer.
  • To explore the potential of targeting sphingosine kinase-1 as a therapeutic strategy for cancer treatment.

Main Methods:

  • Analysis of sphingolipid metabolite levels.
  • Investigation of enzyme activity regulating sphingolipid balance.
  • Evaluation of sphingosine kinase-1 gene and mRNA expression in tumors.
  • Assessment of the effects of sphingosine kinase-1 modulation on apoptosis and cell survival.

Main Results:

  • Sphingosine kinase-1 produces prosurvival sphingosine 1-phosphate and reduces proapoptotic sphingolipids (ceramide and sphingosine).
  • The gene for sphingosine kinase-1 exhibits oncogenic properties, with its mRNA overexpressed in many solid tumors.
  • Overexpression of sphingosine kinase-1 confers resistance to apoptosis and its activity decreases during anticancer treatments.

Conclusions:

  • Sphingosine kinase-1 is a critical regulator of the sphingolipid balance, favoring cell survival.
  • Pharmacological inhibition of sphingosine kinase-1 presents a promising therapeutic target for cancer.
  • Strategies aimed at increasing ceramide/sphingosine and blocking sphingosine 1-phosphate generation could lead to effective tumor cell killing with a favorable therapeutic index.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...